T-oligo as an anticancer agent in colorectal cancer

Biochemical and Biophysical Research Communications

Volumn 446, Issue 2, 2014, Pages 596-601

  Wojdyla, Luke ^a   Stone, Amanda L ^a   Sethakorn, Nan ^b   Uppada, Srijayaprakash B ^a   Devito, Joseph T ^a   Bissonnette, Marc ^b   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Differentiation; DNA damage responses; EGFR; T oligo; Telomere; Therapeutic

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P73; T OLIGO; TELOMERIC REPEAT BINDING FACTOR 2; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SENESCENCE; TELOMERE; UNITED STATES; UPREGULATION;

DIFFERENTIATION; DNA DAMAGE RESPONSES; EGFR; T-OLIGO; TELOMERE; THERAPEUTIC;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; OLIGONUCLEOTIDES; TELOMERE HOMEOSTASIS; TELOMERE-BINDING PROTEINS;

EID: 84897999563     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.013     Document Type: Article

References (37)

1. B. van Steensel, A. Smogorzewska, and T. de Lange TRF2 protects human telomeres from end-to-end fusions Cell 92 1998 401 413
2. T. de Lange T-loops and the origin of telomeres Nat. Rev. Mol. Cell Biol. 5 2004 323 329
3. C.B. Harley, A.B. Futcher, and C.W. Greider Telomeres shorten during ageing of human fibroblasts Nature 345 1990 458 460
4. J. Karlseder, A. Smogorzewska, and T. de Lange Senescence induced by altered telomere state, not telomere loss Science 295 2002 2446 2449
5. M. Ruden, and N. Puri Novel anticancer therapeutics targeting telomerase Cancer Treat. Rev. 39 2013 444 456
6. J.W. Shay, and S. Bacchetti A survey of telomerase activity in human cancer Eur. J. Cancer 33 1997 787 791
7. V. Sekaran, J. Soares, and M.B. Jarstfer Telomere maintenance as a target for drug discovery J. Med. Chem. 57 2014 521 538
8. M.S. Eller, G.Z. Li, R. Firoozabadi, N. Puri, and B.A. Gilchrest Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3′ overhang specific DNA FASEB J. 17 2003 152 162
9. M.S. Eller, N. Puri, I.M. Hadshiew, S.S. Venna, and B.A. Gilchrest Induction of apoptosis by telomere 3′ overhang-specific DNA Exp. Cell Res. 276 2002 185 193
10. G.Z. Li, M.S. Eller, K. Hanna, and B.A. Gilchrest Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides Exp. Cell Res. 301 2004 189 200
11. N. Puri, M.S. Eller, H.R. Byers, S. Dykstra, J. Kubera, and B.A. Gilchrest Telomere-based DNA damage responses: a new approach to melanoma FASEB J. 18 2004 1373 1381
12. A.M. Rankin, S. Sarkar, and D.V. Faller Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells J. Cell. Physiol. 227 2012 2586 2594
13. H.O. Longe, P.B. Romesser, A.M. Rankin, D.V. Faller, M.S. Eller, B.A. Gilchrest, and G.V. Denis Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential Int. J. Cancer 124 2009 473 482
14. M. Yaar, M.S. Eller, I. Panova, J. Kubera, L.H. Wee, K.H. Cowan, and B.A. Gilchrest Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells Breast Cancer Res. 9 2007 R13
15. H. Aoki, E. Iwado, M.S. Eller, Y. Kondo, K. Fujiwara, G.Z. Li, K.R. Hess, D.R. Siwak, R. Sawaya, G.B. Mills, B.A. Gilchrest, and S. Kondo Telomere 3′ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells FASEB J. 21 2007 2918 2930
16. R.T. Pitman, L. Wojdyla, and N. Puri Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma Oncotarget 4 2013 761 771
17. A.M. Rankin, D.V. Faller, and R.A. Spanjaard Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity Anticancer Drugs 19 2008 329 338
18. L. Li, B. Ahmed, K. Mehta, and R. Kurzrock Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer Mol. Cancer Ther. 6 2007 1276 1282
19. J. Silver, and Y.F. Mei Transduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells PLoS One 6 2011 e17532
20. D. Arango, S. Al-Obaidi, D.S. Williams, H. Dopeso, R. Mazzolini, G. Corner, D.S. Byun, A.A. Carr, C. Murone, L. Togel, N. Zeps, L.A. Aaltonen, B. Iacopetta, and J.M. Mariadason Villin expression is frequently lost in poorly differentiated colon cancer Am. J. Pathol. 180 2012 1509 1521
21. I.K. Choi, Y.H. Kim, J.S. Kim, and J.H. Seo PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo Invest. New Drugs 26 2008 283 288
22. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, and R. Pazdur FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 8 2003 303 306
23. S.B. Uppada, T. Erickson, L. Wojdyla, D.N. Moravec, Z. Song, J. Cheng, and N. Puri Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy Int. J. Nanomed. 9 2014 43 53
24. N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia C-Met is a potentially new therapeutic target for treatment of human melanoma Clin. Cancer Res. 13 2007 2246 2253
25. N. Puri, R.T. Pitman, R.E. Mulnix, T. Erickson, A.N. Iness, C. Vitali, Y. Zhao, and R. Salgia Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides Cancer Lett. 343 2014 14 23
26. J.S. Dickey, C.E. Redon, A.J. Nakamura, B.J. Baird, O.A. Sedelnikova, and W.M. Bonner H2AX: functional roles and potential applications Chromosoma 118 2009 683 692
27. D.S. Lim, S.T. Kim, B. Xu, R.S. Maser, J. Lin, J.H. Petrini, and M.B. Kastan ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway Nature 404 2000 613 617
28. J.M. Brown, and B.G. Wouters Apoptosis, p53, and tumor cell sensitivity to anticancer agents Cancer Res. 59 1999 1391 1399
29. E.L. Denchi, and T. de Lange Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1 Nature 448 2007 1068 1071
30. S. Rajpal, and A.P. Venook Targeted therapy in colorectal cancer Clin. Adv. Hematol. Oncol. 4 2006 124 132
31. M.S. Lee, M. Yaar, M.S. Eller, T.M. Runger, Y. Gao, and B.A. Gilchrest Telomeric DNA induces p53-dependent reactive oxygen species and protects against oxidative damage J. Dermatol. Sci. 56 2009 154 162
32. J.H. Petrini The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response Am. J. Hum. Genet. 64 1999 1264 1269
33. Y. Deng, S.S. Chan, and S. Chang Telomere dysfunction and tumour suppression: the senescence connection Nat. Rev. Cancer 8 2008 450 458
34. A. Velcich, W. Yang, J. Heyer, A. Fragale, C. Nicholas, S. Viani, R. Kucherlapati, M. Lipkin, K. Yang, and L. Augenlicht Colorectal cancer in mice genetically deficient in the mucin Muc2 Science 295 2002 1726 1729
35. J. Karlseder, K. Hoke, O.K. Mirzoeva, C. Bakkenist, M.B. Kastan, J.H. Petrini, and T. de Lange The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response PLoS Biol. 2 2004 E240
36. P. Baumann, and C. Price Pot1 and telomere maintenance FEBS Lett. 584 2010 3779 3784
37. D. Leclerc, L. Deng, J. Trasler, and R. Rozen ApcMin/+ mouse model of colon cancer: gene expression profiling in tumors J. Cell. Biochem. 93 2004 1242 1254